← Back to all trials
Active Not Recruiting
NCT02842203
Use of ctDNA for Monitoring of Stage III Colorectal Cancer
Conditions: Stage III Colorectal Cancer
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 137
Sponsor: University of Pittsburgh
Location: University of Pittsburgh Medical Center Pittsburgh Pennsylvania
Summary
This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).
Eligibility Criteria
Inclusion Criteria:
* Men and women with CRC Stage III A, B, or C
* Age ≥18 years
* Willingness to provide blood samples for research purposes
* Ability to understand written informed consent document, and written informed consent provided
Exclusion Criteria:
* Blood sampling would compromise patients overall health such as presence of severe anemia
* Unable to give informed consent
Source: ClinicalTrials.gov (NCT02842203). StuddyBuddy aggregates publicly available trial information.
